Table 1 Demographic and clinical characteristics of early psychosis patients (NAC vs placebo) at baseline (if not specified otherwise)
NAC (n = 10) | Placebo (n = 10) | P value | |
|---|---|---|---|
Age (years) | 25.3 ± 5.7 | 24.8 ± 7.9 | 0.3622 |
Gender (M/F) | 9/1 | 5/5 | 0.1409 |
Mean CPZ, mg/day (baseline) | 264.5 ± 69.29 | 307.8 ± 64.45 | 0.6531 |
Mean CPZ, mg/day (follow-up) | 271.2 ± 65.04 | 418.4 ± 80.27 | 0.1711 |
PANSS baseline: positive symptoms | 13.8 ± 4.8 | 18.0 ± 6.8 | 0.1249 |
PANSS baseline: negative symptoms | 14.6 ± 4.6 | 18.6 ± 6.7 | 0.1377 |
PANSS baseline: total | 32.6 ± 8.5 | 39.4 ± 9.8 | 0.1152 |
Duration of illness (days) | 981.6 ± 810.2 | 663.9 ± 665.3 | 0.3743 |
Diagnosis | |||
Schizophrenia | 6 | 6 | |
Schizoaffective disorder | 2 | 1 | |
Bipolar disorder | 1 | ||
Major depression with psychotic features | 1 | ||
Brief psychotic episode | 1 | 1 | |
Psychosis not otherwise specified | 1 | ||
Antipsychotic medication | |||
Quetiapine | 5 | 3 | |
Clozapine | 1 | ||
Aripiprazole | 1 | 2 | |
Amisulpride | 2 | ||
Risperidone | 1 | 2 | |
Olanzapine | 1 | 1 | |
No medication | 1 | ||
GSHmPFC | n = 9 | n = 8 | |
Baseline (mM) | 0.8432 ± 0.0708 | 1.144 ± 0.06967 | 0.0087 |
Follow-up (mM) | 1.013 ± 0.08315 | 1.096 ± 0.07635 | 0.4803 |
